| |
Find the right match for your research with BioIVT’s extensive inventory of quality normal & disease biospecimens or utilize their global network of 425+ clinical sites for custom procurement. Learn More >> 
|
|
Today’s Big NewsDec 5, 2024 |
| By Gabrielle Masson GSK has penned another neuroscience pact, this time with Danish biotech Muna Therapeutics. The two companies will examine postmortem human brains in efforts to identify several new drug targets for Alzheimer’s disease. |
|
|
|
By James Waldron Massachusetts-based VC shop Atlas Venture has drawn together another $450 million fund to be channeled toward innovative biotechs. |
By Darren Incorvaia Big Pharma-backed immunomodulation biotech Nuvig Therapeutics is moving its lead asset into phase 2 trials and a $161 million series B war chest. |
By Darren Incorvaia British immunology firm Scancell has found a repeat buyer for its monoclonal antibodies. Genmab has plucked another anti-glycan antibody from Scancell’s shelves to the tune of up to $630 million. The deal comes about two years after Genmab snagged its first antibody from Scancell for up to $624M, and it brings Genmab's potential tab to a hefty $1.27 billion. |
By Gabrielle Masson Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering around a preclinical amyotrophic lateral sclerosis program. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Darren Incorvaia Franklin Biolabs, the genetic medicines contract research organization that gene therapy expert James Wilson, M.D., Ph.D., spun out of the University of Pennsylvania earlier this year, has named Vatsala Naageshwaran, Ph.D., as its new CEO. |
By Noah Tong The two drugs treat sickle cell disease, the stated first priority of the new CMS model set to begin in January. |
By Nick Paul Taylor AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. The drugmaker successfully defended itself against claims senior staff ignored requests to unlike LinkedIn posts but the U.K. marketing watchdog still found the company had brought discredit on the industry in two cases. |
By Paige Minemyer UnitedHealth Group abruptly ended its investor day event on Wednesday morning as news reports surfaced that the CEO of its health plan division had been fatally shot. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
